Komori
Eisai (4523) · InitiativeFirst stated

Entry into China’s generic pharmaceuticals business

First written in FY2016. . Latest entry: FY2016.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Entry into China’s Generic Pharmaceuticals Business through the Acquisition of 遼寧天医生物製薬A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2016First statedAnnual report

    「本買収により、当社は中国において、現在展開している新薬を中心とした事業に加えてジェネリック医薬品事業に参入します。」

    2015年12月28日に遼寧天医生物製薬株式有限公司の全株式取得を完了し、GMP工場から高品質製品を安定供給する方針を示している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Entry into China’s generic pharmaceuticals business | Eisai Co.,Ltd. (4523) | Komori